Seattle Genetics (SGEN) to Present Data from Several ADCETRIS Trials at ASCO
Tweet Send to a Friend
Seattle Genetics, Inc. (Nasdaq: SGEN) reports that data from several clinical trials of ADCETRIS (brentuximab vedotin) will be presented at ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
